Suppr超能文献

亚太地区数据库在疫苗安全合作监测中的适用性。

Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety.

机构信息

Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.

Vaccine Medical, Scientific and Clinical Affairs, Pfizer Inc., New York, New York, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):843-857. doi: 10.1002/pds.5214. Epub 2021 Mar 23.

Abstract

INTRODUCTION

Information regarding availability of electronic healthcare databases in the Asia-Pacific region is critical for planning vaccine safety assessments particularly, as COVID-19 vaccines are introduced. This study aimed to identify data sources in the region, potentially suitable for vaccine safety surveillance. This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).

METHODS

Nineteen countries targeted for database reporting were identified using published country lists and review articles. Surveillance capacity was assessed using two surveys: a 9-item introductory survey and a 51-item full survey. Survey questions related to database characteristics, covariate and health outcome variables, vaccine exposure characteristics, access and governance, and dataset linkage capability. Other questions collated research/regulatory applications of the data and local publications detailing database use for research.

RESULTS

Eleven databases containing vaccine-specific information were identified across 8 countries. Databases were largely national in coverage (8/11, 73%), encompassed all ages (9/11, 82%) with population size from 1.4 to 52 million persons. Vaccine exposure information varied particularly for standardized vaccine codes (5/11, 46%), brand (7/11, 64%) and manufacturer (5/11, 46%). Outcome data were integrated with vaccine data in 6 (55%) databases and available via linkage in 5 (46%) databases. Data approval processes varied, impacting on timeliness of data access.

CONCLUSIONS

Variation in vaccine data availability, complexities in data access including, governance and data release approval procedures, together with requirement for data linkage for outcome information, all contribute to the challenges in building a distributed network for vaccine safety assessment in the Asia-Pacific and globally. Common data models (CDMs) may help expedite vaccine safety research across the region.

摘要

简介

了解亚太地区电子医疗数据库的可用性对于规划疫苗安全性评估至关重要,特别是在引入 COVID-19 疫苗的情况下。本研究旨在确定该地区潜在适合疫苗安全性监测的数据来源。本文由国际药物流行病学学会(ISPE)认可。

方法

使用已发表的国家名单和评论文章,确定了 19 个目标国家/地区进行数据库报告。使用两项调查评估监测能力:一项 9 项介绍性调查和一项 51 项全面调查。调查问题涉及数据库特征、协变量和健康结果变量、疫苗暴露特征、访问和治理以及数据集链接能力。其他问题则收集了数据的研究/监管应用以及详细说明数据库用于研究的本地出版物。

结果

在 8 个国家/地区共发现了 11 个包含疫苗特定信息的数据库。这些数据库在很大程度上是全国性的(8/11,73%),涵盖了所有年龄段(9/11,82%),人口规模从 140 万到 5200 万不等。疫苗暴露信息差异很大,特别是标准化疫苗代码(5/11,46%)、品牌(7/11,64%)和制造商(5/11,46%)。6 个(55%)数据库将结果数据与疫苗数据集成,5 个(46%)数据库可通过链接获取。数据审批程序各不相同,这影响了数据访问的及时性。

结论

疫苗数据可用性的差异、数据访问的复杂性,包括治理和数据发布审批程序,以及对结果信息进行数据链接的要求,都对在亚太地区和全球建立疫苗安全性评估分布式网络带来了挑战。通用数据模型(CDM)可能有助于加快该地区的疫苗安全性研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验